The trial findings complement the updated US dyslipidemia guidelines that promote early and intensive LDL lowering.

Shares of Insmed rose about 7% after positive late-stage data for its lung disease drug Arikayce, with analysts pointing to a potential expansion in the drug’s addressable market. Morgan Stanley said ...

VESALIUS-CV further extends PCSK9 inhibitor's primary prevention benefits ...

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of ...

Oral brepocitinib 30 mg was superior to placebo for treating dermatomyositis in adults already receiving standard therapies, according to phase 3 data presented at the American Academy of Dermatology ...

Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more ...

BCVA can remain deceptively stable until late RP and becomes insensitive at profound vision loss, motivating ...

Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company ...

Three-year outcomes from the PERFORMANCE II trial studying the Neuroguard Integrated Embolic Protection (IEP) 3-in-1 Carotid Sten ...

FDA fast track designation applies to ALK+ NSCLC progressing after ≥2 ALK TKIs, reflecting limited post-lorlatinib ...

A new analysis from Oxford Brookes University warns that Indonesia’s songbird trade is creating a hidden extinction risk: as ...